{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022762","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.877013+00:00","generated_at":"2026-06-02T02:16:58.181101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avalo Q1 net loss $121.3M driven by warrant fair value charge; cash $110M into 2027","bullets":["Cash and cash equivalents $110.2M at March 31, 2024; expects runway through AVTX-009 Phase 2 data readout and into 2027.","Net loss $121.3M includes $79.3M loss from excess of warrant fair value over private placement proceeds and $27.5M acquired IPR&D expense.","Closed private placement for up to $185M gross; initial $115.6M received; warrants classified as liability with $194.9M fair value.","Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026; trial to start this year.","Strategic review underway for quisovalimab (AVTX-002) and AVTX-008 programs; no revenue in Q1 2024 vs $475K a year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022762","json":"https://secwatch.observer/filing/0001628280-24-022762.json","markdown":"https://secwatch.observer/filing/0001628280-24-022762.md","text":"https://secwatch.observer/filing/0001628280-24-022762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/0001628280-24-022762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/avtx-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:16:58.181101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33294bfb1c9417529ccba74ac1e8ca8466db07e6","claim":"Avalo Therapeutics, Inc. reported first quarter of 2024 results: net income net loss of $121.3 million.","evidence_excerpt":"For the three months ended March 31, 2024, Avalo generated a net loss of $121.3 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024022762/0001628280-24-022762-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Net income","value":"net loss of $121.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}